Expression of HER-2/neu in Oral Squamous Cell Carcinoma

Mirza, Sana; Hadi, Naila Irum; Pervaiz, Shahid; Khan, Sultan Zeb; Mokeem, Sameer A; Abduljabbar, Tariq; Al-Hamoudi, Nawwaf; Vohra, Fahim

doi:10.31557/apjcp.2020.21.5.1465

Cited by 13 publications

(8 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The estimated pooled prevalence of HER2 positivity in squamous CC was above 4%. Although relatively low in general, it looks slightly higher than figures reported in squamous carcinomas of other primary sites [ 101 , 102 ]. On the other hand, the non-squamous CC subgroup was composed of numerous, sometimes distinct entities ( Fig 10 and S11 File ).…”

Section: Discussioncontrasting

confidence: 55%

Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis

Itkin

García²,

Straminsky

et al. 2021

PLoS ONE

View full text Add to dashboard Cite

The reported rates of HER2 positivity in cervical cancer (CC) range from 0% to 87%. The importance of HER2 as an actionable target in CC would depend on HER2 positivity prevalence. Our aim was to provide precise estimates of HER2 overexpression and amplification in CC, globally and by relevant subgroups. We conducted a PRISMA compliant meta-analytic systematic review. We searched Medline, EMBASE, Cochrane database, and grey literature for articles reporting the proportion of HER2 positivity in CC. Studies assessing HER2 status by immunohistochemistry or in situ hybridization in invasive disease were eligible. We performed descriptive analyses of all 65 included studies. Out of these, we selected 26 studies that used standardized American Society of Clinical Oncology / College of American Pathologists (ASCO/CAP) Guidelines compliant methodology. We conducted several meta-analyses of proportions to estimate the pooled prevalence of HER2 positivity and subgroup analyses using geographic region, histology, tumor stage, primary antibody brand, study size, and publication year as moderators. The estimated pooled prevalence of HER2 overexpression was 5.7% (CI 95%: 1.5% to 11.7%) I2 = 87% in ASCO/CAP compliant studies and 27.0%, (CI 95%: 19.9% to 34.8%) I2 = 96% in ASCO/CAP non-compliant ones, p < 0.001. The estimated pooled prevalence of HER2 amplification was 1.2% (CI 95%: 0.0% to 5.8%) I2 = 0% and 24.9% (CI 95%: 12.6% to 39.6%) I2 = 86%, respectively, p = 0.004. No other factor was significantly associated with HER2 positivity rates. Our results suggest that a small, but still meaningful proportion of CC is expected to be HER2-positive. High heterogeneity was the main limitation of the study. Variations in previously reported HER2 positivity rates are mainly related to methodological issues.

show abstract

Section: Discussioncontrasting

confidence: 55%

Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis

Itkin

García²,

Straminsky

et al. 2021

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…CD34 is a cluster of differentiation molecule that is seen on several cells inside the body. It is a glycoprotein that is present on the surface of the cell, which works as a cell-cell adhesion factor [ 8 , 9 , 10 ]. Cells that express CD34 are endothelial cells of blood vessels excluding lymphatics (except pleural lymphatics), mast cells, a sub-population of dendritic cells (which are factor XIIIa negative) in the interstitium and around the adnexa of the dermis of the skin.…”

Section: Introductionmentioning

confidence: 99%

Expression of CD34 and α-SMA Markers in Oral Squamous Cell Carcinoma Differentiation. A Histological and Histo-Chemical Study

Maqsood

Ali

Zaffar

et al. 2020

IJERPH

Self Cite

View full text Add to dashboard Cite

To reduce morbidity and mortality rates of OSCC cases, early diagnosis, assessment of behavior and prognostic estimates are vital. This study analyzed the expression of CD34 and alpha smooth muscle actin (α-SMA) in OSCC, to establish their significance in diagnosis and prognosis. Primary cases of OSCC, diagnosed with excisional biopsy at multiple cancer treatment centers, were included. Tissue sections were embedded and stained with H & E for histological differentiation and invasion of tumor vessel. Immunohistochemistry was performed using antibodies against CD34 and α-SMA. The chi-square and Pearson correlation coefficient (r) tests were applied for data analysis. Eighty patients with fifty males (62.5%) and thirty females (37.5%) and mean age of 45 ± 14.1 years were evaluated. Buccal mucosa was the most common site for OSCC lesions [36 (45%)]; 47.5% of lesions were moderately differentiated and 33.8% were well-differentiated lesions. Invasion of tumor vessels was observed in 35% of specimens. A significant association was seen between CD34 expression and histological grading of OSCC (p < 0.002). Among all poorly differentiated OSCC specimens, expression of CD 34 was low and α-SMA was high. CD 34 is a critical prognostic factor in OSCC diagnosis and increased α-SMA-positive myofibroblasts may indicate aggressive OSCC behavior.

show abstract

“…In a previous study, it was found that HER2 was expressed in oral cancers, and that the administration of an anti-HER2 mAb (clone H 2 Mab-19, mouse IgG 2b ) resulted in antitumor activity against HSC-2 and SAS xenografts ( 23 ). By contrast, Mirza et al ( 24 ) demonstrated that only one case out of 140 OSCCs was HER2-positive; as such, the feasibility of anti-HER2 therapy for OSCC remains uncertain. In another study, the authors developed a sensitive and specific mAb against EGFR that recognized a distinct epitope (clone EMab-17, mouse IgG 2a ) and that elicited both ADCC and CDC, as well as antitumor activity against HSC-2 and SAS xenografts ( 21 ).…”

Section: Discussionmentioning

confidence: 98%

Anti‑EGFR monoclonal antibody 134‑mG2a exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma

et al. 2020

View full text Add to dashboard Cite

The epidermal growth factor receptor (EGFR), a transmembrane receptor and member of the human epidermal growth factor receptor (HER) family of receptor tyrosine kinases, is a critical mediator of cell growth and differentiation. EGFR forms homo- or heterodimers with other HER family members to activate downstream signaling cascades in a number of cancer cells. In a previous study, the authors established an anti-EGFR monoclonal antibody (mAb), EMab-134, by immunizing mice with the ectodomain of human EGFR. EMab-134 binds specifically to endogenous EGFR and can be used to detect receptor on oral cancer cell lines by flow cytometry and western blot analysis; this antibody is also effective for the immunohistochemical evaluation of oral cancer tissues. In the present study, the subclass of EMab-134 was converted from IgG 1 to IgG 2a (134-mG 2a ) to facilitate antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The dissociation constants ( K D s) of EMab-134 and 134-mG 2a against EGFR-expressing CHO-K1 (CHO/EGFR) cells were deter-mined by flow cytometry to be 3.2×10 −9 M and 2.1×10 −9 M, respectively; these results indicate that 134-mG 2a has a higher binding affinity than EMab-134. The 134-mG 2a antibody was more sensitive than EMab-134 with respect to antigen detection in oral cancer cells in both western blot analysis and immunohistochemistry applications. Analysis in vitro revealed that 134-mG 2a contributed to high levels of ADCC and CDC in experiments targeting CHO/EGFR, HSC-2, and SAS cells. Moreover, the in vivo administration of 134-mG 2a significantly inhibited the development of CHO/EGFR, HSC-2, and SAS mouse xenografts in comparison to the results observed in response to EMab-134. Taken together, the findings of the present study demonstrate that the newly-formulated 134-mG 2a is useful for detecting EGFR by flow cytometry, western blot analysis and immunohistochemistry. Furthermore, the in vivo results suggested that it may also be useful as part of a therapeutic regimen for patients with EGFR-expressing oral cancer.

show abstract

Expression of HER-2/neu in Oral Squamous Cell Carcinoma

Cited by 13 publications

References 39 publications

Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis

Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis

Expression of CD34 and α-SMA Markers in Oral Squamous Cell Carcinoma Differentiation. A Histological and Histo-Chemical Study

Anti‑EGFR monoclonal antibody 134‑mG2a exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma

Contact Info

Product

Resources

About